Rilutek (riluzole) vs Clenbuterol ()
Rilutek (riluzole) vs Clenbuterol ()
Rilutek (riluzole) is a medication specifically approved for the treatment of amyotrophic lateral sclerosis (ALS), and it works by reducing the release of glutamate, which is thought to be involved in the damage to motor neurons characteristic of the disease. Clenbuterol, on the other hand, is a bronchodilator that is used primarily for treating asthma and other breathing disorders, but it is not approved for ALS and has a different mechanism of action, primarily affecting the smooth muscle in the airways to improve breathing. When deciding between these medications, it is crucial to consider the specific condition being treated: Rilutek is the option for ALS, while Clenbuterol would be considered for respiratory conditions, and neither should be used off-label without the guidance of a healthcare provider.
Difference between Rilutek and Clenbuterol
| Metric | Rilutek (riluzole) | Clenbuterol |
|---|---|---|
| Generic name | Riluzole | Clenbuterol |
| Indications | Amyotrophic lateral sclerosis (ALS) | Asthma, other obstructive pulmonary diseases (off-label for weight loss and performance enhancement) |
| Mechanism of action | Reduces glutamate release, which may protect neurons from excitotoxicity | Beta-2 agonist that leads to smooth muscle relaxation and bronchodilation |
| Brand names | Rilutek, Tiglutik, Exservan | Not available as a brand-name drug in the U.S. (commonly known as Clenbuterol) |
| Administrative route | Oral | Oral, inhalation (not FDA approved) |
| Side effects | Dizziness, gastrointestinal disturbances, elevated liver enzymes, decreased lung function | Tachycardia, tremors, headaches, muscle cramps, dry mouth, palpitations |
| Contraindications | Liver impairment, caution in patients with lung or renal impairment | Cardiac arrhythmias, coronary artery disease, hypertension |
| Drug class | Glutamate antagonist | Beta-2 adrenergic agonist |
| Manufacturer | Sanofi | Varies by country and formulation; not manufactured for legitimate human use in the U.S. |
Efficacy
Efficacy of Rilutek (Riluzole) for ALS
Rilutek, known generically as riluzole, is a medication that has been approved by regulatory agencies for the treatment of Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. The efficacy of Rilutek in the treatment of ALS has been demonstrated in clinical trials, where it has been shown to slow the progression of the disease. Riluzole is believed to reduce the damage to motor neurons by decreasing the release of glutamate, which can be toxic to neurons in high concentrations.
In clinical studies, Rilutek has been shown to prolong survival in individuals with ALS. The most cited study that led to its approval showed that patients taking Rilutek had a modest increase in survival time compared to those taking a placebo. The median survival time extension is approximately two to three months. However, it is important to note that the response to Rilutek can vary, and not all patients may experience the same level of benefit.
Efficacy of Clenbuterol for ALS
Clenbuterol is a medication that is primarily known as a bronchodilator used for treating asthma. However, its use in the treatment of Amyotrophic Lateral Sclerosis (ALS) is considered off-label, and the evidence supporting its efficacy for this indication is limited and not well-established. Clenbuterol has been studied for its potential neuroprotective and muscle-building effects, which could theoretically be beneficial in a disease like ALS that involves muscle wasting and weakness.
There is a lack of large-scale, definitive clinical trials that specifically evaluate the efficacy of Clenbuterol in patients with ALS. Some preclinical studies and small clinical trials have suggested that Clenbuterol may have some neuroprotective effects or may help in reducing muscle loss in ALS. However, these findings are preliminary, and Clenbuterol is not widely recognized or approved for the treatment of ALS by regulatory authorities. Therefore, its use in this context should be considered experimental and undertaken with caution, under the guidance of a healthcare professional familiar with the disease.
Regulatory Agency Approvals
Rilutek
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medicines & Healthcare products Regulatory Agency (MHRA), United Kingdom
-
Medsafe (NZ)
Clenbuterol
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Access Rilutek or Clenbuterol today
If Rilutek or Clenbuterol are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us